Pentoxifylline adjunct to risperidone for negative symptoms of stable schizophrenia: a randomized, double-blind, placebo-controlled trial

Ahmad Shamabadi, Elham-Sadat Rafiei-Tabatabaei, Kimia Kazemzadeh, Kimia Farahmand, Bita Fallahpour, Mohammad-Reza Khodaei Ardakani, Shahin Akhondzadeh · 2024

Read Pentoxifylline adjunct to risperidone for negative symptoms of stable schizophrenia: a randomized, double-blind, placebo-controlled trial by Ahmad Shamabadi, Elham-Sadat Rafiei-Tabatabaei, Kimia Kazemzadeh, Kimia Farahmand, Bita Fallahpour, Mohammad-Reza Khodaei Ardakani, Shahin Akhondzadeh (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11781224.txt.

Description

Ahmad Shamabadi and co-authors test whether pentoxifylline, a drug that improves blood flow and calms inflammation, can ease the negative symptoms of schizophrenia. Those symptoms, such as flat affect and withdrawal, lack good treatments. The trial enrolled stable outpatients who had taken risperidone for at least two months. Half received pentoxifylline twice a day for eight weeks; the other half received a matched placebo.

The pentoxifylline group improved more on the negative symptom scale, with the gap clear by week four and larger by week eight. Their response rate was also better. Depression scores, movement side effects, and other symptom scores were similar in both groups. Remission came to 37.1 percent on the drug against 14.7 percent on placebo, though that gap was not statistically firm. The authors call the drug safe, tolerable, and helpful for the primary negative symptoms of chronic schizophrenia.

Catalog record

CREATORAhmad Shamabadi, Elham-Sadat Rafiei-Tabatabaei, Kimia Kazemzadeh, Kimia Farahmand, Bita Fallahpour, Mohammad-Reza Khodaei Ardakani, Shahin Akhondzadeh
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11781224

Browse the full library · About the Tower of Babel